Weigang Xiu Qianqian Zhang Min Yu Yin Huang Meijuan Huang
10.3389/fonc.2021.630256
Front Oncol
2021 Apr 22;11:630256.
acquired kras mutation drug-resistance immune checkpoint inhibitor non–small cell lung cancer osimertinib
CC BY
https://pubmed.ncbi.nlm.nih.gov/33968729/
Case Reports
PMC8100222
33968729
Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
2021